Prevalence of conventional risk factors in patients with coronary heart disease.

CONTEXT It is commonly suggested that more than 50% of patients with coronary heart disease (CHD) lack any of the conventional risk factors (cigarette smoking, diabetes, hyperlipidemia, and hypertension). This claim implies that other factors play a significant role in CHD and has led to considerable interest in nontraditional risk factors and genetic causes of CHD. OBJECTIVE To determine the prevalence of the 4 conventional risk factors among patients with CHD. DESIGN, SETTING, AND PATIENTS In 2002-2003, we analyzed data for 122458 patients enrolled in 14 international randomized clinical trials of CHD conducted during the prior decade. Patients included 76716 with ST-elevation myocardial infarction, 35527 with unstable angina/non-ST-elevation myocardial infarction, and 10215 undergoing percutaneous coronary intervention. MAIN OUTCOME MEASURES Prevalence of each conventional risk factor and number of conventional risk factors present among patients with CHD, compared between men and women and by age at trial entry. RESULTS Among patients with CHD, at least 1 of the 4 conventional risk factors was present in 84.6% of women and 80.6% of men. In younger patients (men < or =55 years and women < or =65 years) and most patients presenting either with unstable angina or for percutaneous coronary intervention, only 10% to 15% of patients lacked any of the 4 conventional risk factors. This pattern was largely independent of sex, geographic region, trial entry criteria, or prior CHD. Premature CHD was related to cigarette smoking in men and cigarette smoking and diabetes in women. Smoking decreased the age at the time of CHD event (at trial entry) by nearly 1 decade in all risk factor combinations. CONCLUSIONS In direct contrast with conventional thinking, 80% to 90% of patients with CHD have conventional risk factors. Although research on nontraditional risk factors and genetic causes of heart disease is important, clinical medicine, public health policies, and research efforts should place significant emphasis on the 4 conventional risk factors and the lifestyle behaviors causing them to reduce the epidemic of CHD.

[1]  D Kromhout,et al.  Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. , 1995, Archives of internal medicine.

[2]  H. Pereira,et al.  Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial , 2001, The Lancet.

[3]  C. Hennekens.  Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. , 1998, Circulation.

[4]  Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. , 1997, Lancet.

[5]  M. Rubenfire,et al.  The role of inflammation and infection in coronary artery Disease: A clinical perspective , 2002 .

[6]  J. Avorn,et al.  The exclusion of the elderly and women from clinical trials in acute myocardial infarction. , 1992, JAMA.

[7]  James F Sallis,et al.  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. , 2002, Circulation.

[8]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[9]  M. Simoons.  Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial , 2001, The Lancet.

[10]  Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. , 1998, The New England journal of medicine.

[11]  V. Pavlik,et al.  Characteristics of patients with uncontrolled hypertension in the United States. , 2001, The New England journal of medicine.

[12]  W. Kannel.  Coronary heart disease risk factors in the elderly. , 2002, The American journal of geriatric cardiology.

[13]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[14]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.

[15]  V. Pavlik,et al.  Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. , 2000, Archives of internal medicine.

[16]  A. Folsom,et al.  Population awareness and control of hypertension and hypercholesterolemia. The Atherosclerosis Risk in Communities study. , 1995, Archives of internal medicine.

[17]  W. Aronow,et al.  41‐Month Follow‐Up of Risk Factors Correlated With New Coronary Events in 708 Elderly Patients , 1989, Journal of the American Geriatrics Society.

[18]  A. Sharrett,et al.  Risk factors for popliteal and carotid wall thicknesses in the Atherosclerosis Risk in Communities (ARIC) Study. , 1999, American journal of epidemiology.

[19]  E. Braunwald.  Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. , 1997, The New England journal of medicine.

[20]  R. Beaglehole,et al.  The real contribution of the major risk factors to the coronary epidemics: time to end the "only-50%" myth. , 2001, Archives of internal medicine.

[21]  Gebhardt,et al.  International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina , 1998 .

[22]  L. Tavazzi.  Clinical epidemiology of acute myocardial infarction. , 1999, American heart journal.

[23]  R. D'Agostino,et al.  Sudden coronary death in women. , 1998, American heart journal.

[24]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[25]  D Kromhout,et al.  Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. , 1995, JAMA.

[26]  S. Bowlin,et al.  Validity of cardiovascular disease risk factors assessed by telephone survey: the Behavioral Risk Factor Survey. , 1993, Journal of clinical epidemiology.

[27]  A. Newman,et al.  Type 2 diabetes in older well-functioning people: who is undiagnosed? Data from the Health, Aging, and Body Composition study. , 2001, Diabetes care.

[28]  O. Wiklund,et al.  Cholesterol reduction and clinical benefit. Are there limits to our expectations? , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[29]  Epilog Investigators,et al.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. , 1997, The New England journal of medicine.

[30]  E. Topol.  A comparison of reteplase with alteplase for acute myocardial infarction. , 1998, The New England journal of medicine.

[31]  R. Califf,et al.  A Comparison of Directional Atherectomy with Coronary Angioplasty in Patients with Coronary Artery Disease , 1993 .

[32]  C. Naylor,et al.  Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants: a population-based comparison. , 1996, Journal of the American College of Cardiology.

[33]  R. Mulcahy.  The health benefits of smoking cessation. , 1990, Irish medical journal.

[34]  L. Lemberg,et al.  Fifty percent of patients with coronary artery disease do not have any of the conventional risk factors. , 1998, American journal of critical care : an official publication, American Association of Critical-Care Nurses.

[35]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[36]  M. Simoons.  A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. , 1996, The New England journal of medicine.

[37]  A. Hamsten,et al.  Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study , 2002, The Lancet.

[38]  Randomized, Placebo-Controlled Trial of Titrated Intravenous Lamifiban for Acute Coronary Syndromes , 2002, Circulation.

[39]  A. Quyyumi,et al.  Predisposition to Atherosclerosis by Infections: Role of Endothelial Dysfunction , 2002, Circulation.

[40]  F Levi,et al.  Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world , 2002, Heart.

[41]  Stgrp Capture,et al.  Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study , 1997, The Lancet.

[42]  Vincent Mooser,et al.  Contribution of major cardiovascular risk factors to familial premature coronary artery disease: the GENECARD project. , 2002, Journal of the American College of Cardiology.

[43]  W. Willett,et al.  Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. , 1987, The New England journal of medicine.

[44]  E. Barrett-Connor,et al.  Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. , 1991, JAMA.

[45]  A. Döring,et al.  Classical risk factors and their impact on incident non-fatal and fatal myocardial infarction and all-cause mortality in southern Germany. Results from the MONICA Augsburg cohort study 1984-1992. Monitoring Trends and Determinants in Cardiovascular Diseases. , 1998, European heart journal.

[46]  J. Willerson,et al.  Prospects for cardiovascular research. , 2001, JAMA.

[47]  S. Syme,et al.  Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: mortality. , 1975, American journal of epidemiology.

[48]  J. Neaton,et al.  Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.